FDA · Advisory committee

FDA advisory committee to review seven peptide-related bulk drug substances

FDA scheduled a two-day Pharmacy Compounding Advisory Committee meeting to discuss whether BPC-157, KPV, TB-500, MOTS-c, emideltide/DSIP, Semax, and Epitalon-related substances should be included on the 503A Bulks List. The committee provides advice; the meeting itself is not a final agency determination.

Scheduled legal stageJul 23, 2026 record dateUnited States jurisdiction

Open the primary-source record

Record status

Scheduled public meeting

Agency: U.S. Food and Drug Administration
Action: Public meeting
Stage: Scheduled
Last verified: Jul 10, 2026

Source-backed timeline

Status history

Jul 23, 2026Scheduled public meetingSource

Editorial boundary: Peptide Report summarizes the public source and preserves its procedural stage. This page does not convert an allegation, proposal, advisory discussion, or warning into a final legal conclusion.

Back to all Regulatory Watch records